WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.


CLSI NBS03

Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns, 2nd Edition

This guideline describes the recommended protocols for screening preterm, low birth weight, and sick newborns for hearing loss, critical congenital heart defects, and diseases detectable through newborn dried blood spot screening.

Member price:

List Price:
Log in/sign up to see price and add to cart

Details

Chairholder: Julie Luedtke, BS

Date of Publication: August 12, 2019

Order Code PDF: CLSI NBS03Ed2E
ISBN Number: 978-1-68440-053-9

Order Code Print: CLSI NBS03Ed2
ISBN Number: 978-1-68440-052-2

Edition: Second

Pages: 82

CLSI NBS03 Additional Details

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

This document was formerly sold under the code ILA31.

CLSI NBS03 Abstract

Clinical and Laboratory Standards Institute guideline NBS03—Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns describes newborn screening (NBS) of preterm, low birth weight (LBW), and sick newborns worldwide to detect treatable diseases before physical damage can occur. In developed countries, treatment advances have improved survival rates, making early disease detection by NBS even more important. The physiological states associated with preterm, LBW, and sick newborns and the treatments received directly affect the reliability of results for many diseases screened in public health by newborn dried blood spot screening, newborn hearing screening, and critical congenital heart disease (CCHD) screening. This guideline describes the effects of maternal and newborn conditions, as well as treatments given to newborns, that may affect NBS results. This guideline also provides the rationale for recommended screening intervals designed to minimize the risk of missing or delaying a diagnosis in an affected newborn. This guideline is intended for use by those involved in any aspect of NBS specimen collection, hearing screening, CCHD screening, and follow-up, including health care providers, public health professionals, and others concerned with newborn health and welfare.